TFF Pharmaceuticals, Inc. (TFFP)
NASDAQ: TFFP · IEX Real-Time Price · USD
1.860
-0.040 (-2.11%)
Jul 22, 2024, 9:43 AM EDT - Market open
TFF Pharmaceuticals Employees
TFF Pharmaceuticals had 19 employees as of December 31, 2023. The number of employees increased by 4 or 26.67% compared to the previous year.
Employees
19
Change (1Y)
4
Growth (1Y)
26.67%
Revenue / Employee
$46,617
Profits / Employee
-$1,048,790
Market Cap
5.76M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CareMax | 1,450 |
| PolyPid | 62 |
| Ainos | 46 |
| Hepion Pharmaceuticals | 22 |
| Soligenix | 15 |
| Sonoma Pharmaceuticals | 10 |
| Oragenics | 5 |
| Titan Pharmaceuticals | 4 |
TFFP News
- 26 days ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering - GlobeNewsWire
- 3 months ago - TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting - GlobeNewsWire